SOBI: Business Man
Rare disease drug developer Swedish Orphan Biovitrum AB (Sobi) has named Guido Oelkers as the companys new President and CEO. Oelkers, who holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London, joins from BSN Medical GmbH, where he held the position of CEO.
Previously, he was President and CEO of Swedish medtech company Gambro and CEO of Invida. He also worked in commercial operations roles in companies such as Nycomed, DKSH Group and Aventis. Oelkers is to relocate to Stockholm to take up his post.L
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium